Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR Mutations”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Active Not RecruitingNCT03333343
What this trial is testing

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

Who this might be right for
EGFR-mutant Non-small Cell Lung Cancer
Novartis Pharmaceuticals 105
Testing effectiveness (Phase 2)Ended earlyNCT02095782
What this trial is testing

Chemotherapy and Erlotinib for Lung Cancer With Low Abundance Epidermal Growth Factor Receptor Mutation

Who this might be right for
Non-small-cell Lung Cancer
Guangdong Association of Clinical Trials 10
Testing effectiveness (Phase 2)Looking for participantsNCT06706076
What this trial is testing

BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)
BlossomHill Therapeutics 675
Testing effectiveness (Phase 2)Looking for participantsNCT06222489
What this trial is testing

Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT

Who this might be right for
Non-Small Cell Lung CarcinomaAdvanced Non-Small Cell Squamous Lung CancerEGFR Gene Mutation
The Netherlands Cancer Institute 16
Testing effectiveness (Phase 2)Study completedNCT04184921
What this trial is testing

Combination of Osimertinib and Aspirin to Treat EGFR Mutation NSCLC Patients

Who this might be right for
Lung Cancer Non-small Cell Stage IV
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University 216
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06971406
What this trial is testing

High-Dose Firmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed in the Treatment of EGFR-Mutated Non-Small Cell Lung Cancer With Leptomeningeal Metastasis

Who this might be right for
Non Small Cell Lung CancerEGFR MutationLeptomeningeal Metastases+1 more
Qiming Wang 100
Large-scale testing (Phase 3)UnknownNCT04797806
What this trial is testing

Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Concomitant Mutation NSCLC

Who this might be right for
Non Small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital 206
Testing effectiveness (Phase 2)UnknownNCT03460275
What this trial is testing

Osimertinib as First-line Therapy for Patients With Late-stage Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Sun Yat-sen University 100
Not applicableLooking for participantsNCT05997719
What this trial is testing

Exploring Cancer Evolution, Prognostic and Predictive Biomarkers in EGFR-mutant NSCLC

Who this might be right for
Non-small Cell Lung Cancer
Sun Yat-sen University 150
Testing effectiveness (Phase 2)Active Not RecruitingNCT05786430
What this trial is testing

Lazertinib+Pemetrexed/Carboplatin in Patients With EGFR Sensitizing Mutation Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Failed to Prior Lazertinib

Who this might be right for
Non-small Cell Lung Cancer
Yonsei University 87
Not applicableStudy completedNCT01260038
What this trial is testing

Study in NSCLC: is Timely Analysis of EGFR-mutation Status Feasible in Region Antwerp, Belgium.

Who this might be right for
Non Small Cell Lung Cancer
University Hospital, Antwerp 107
Testing effectiveness (Phase 2)Active Not RecruitingNCT05526755
What this trial is testing

5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)

Who this might be right for
Stage II-IIIB Non-small Cell Lung Carcinoma
AstraZeneca 188
Testing effectiveness (Phase 2)Ended earlyNCT02192697
What this trial is testing

An Open Study of ASP8273 in Patients With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations

Who this might be right for
Non-small Cell Lung Cancer
Astellas Pharma Inc 124
Testing effectiveness (Phase 2)UnknownNCT03420079
What this trial is testing

A Phase I Study of FCN-411 in Advanced Non-small Cell Lung Cancer Chinese Patients With EGFR Positive Mutation

Who this might be right for
Lung Cancer
Ahon Pharmaceutical Co., Ltd. 90
Not applicableStudy completedNCT03370770
What this trial is testing

Afatinib Osimertinib Sequencing NIS

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim 204
Testing effectiveness (Phase 2)UnknownNCT02226757
What this trial is testing

Paclitaxel-trastuzumab in EGFR-mutated NSCLC Patients

Who this might be right for
NSCLCHER2-expressionEGFR-mutation
Amsterdam UMC, location VUmc 16
Testing effectiveness (Phase 2)UnknownNCT03399669
What this trial is testing

The Continuation of Gefitinib Treatment Beyond Progression in Non-small Cell Lung Cancer Patients With EGFR Mutation

Who this might be right for
Non-small Cell Lung Cancer
Samsung Medical Center 100
Not applicableUnknownNCT06352502
What this trial is testing

An Observational Study of Furmonertinib for EGFR Mutation-positive NSCLC Patients With Brain Metastasis

Who this might be right for
EGF-R Positive Non-Small Cell Lung CancerCNS Metastases
Tang-Du Hospital 30
Not applicableLooking for participantsNCT01994057
What this trial is testing

A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)EGFR-TKI Resistant MutationEGFR-TKI Sensitizing Mutation+2 more
Sun Yat-sen University 1,000
Large-scale testing (Phase 3)Active Not RecruitingNCT05120349
What this trial is testing

A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection

Who this might be right for
Non-Small Cell Lung Cancer
AstraZeneca 390
Next Page